Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Abivax SA プロフィール



企業コードABVX

会社名Abivax SA

上場日Jun 26, 2015

最高経営責任者「CEO」de Garidel (Marc)

従業員数- -

証券種類Depository Receipt

決算期末- -

本社所在地7-11 Boulevard Haussmann

都市PARIS

証券取引所NASDAQ OMX - NASDAQ BASIC

国France

郵便番号75009

電話番号33153830963

ウェブサイトhttps://www.abivax.com/

企業コードABVX

上場日Jun 26, 2015

最高経営責任者「CEO」de Garidel (Marc)

Abivax SAの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Kevin Shan, Ph.D.

Vice President, Global Head - Biometrics

Dr. Dominik Hoechli, M.D.

Independent Director

Ms. Nadege Briancon-Eris, Ph.D.

Senior Vice President, Global Head - Program Management

Ms. Mary Mantock

Senior Vice President, Global Head - Regulatory Affairs

Ms. Hema Keshava

Senior Vice President - Finance

Dr. Douglas Jacobstein, M.D.

Senior Vice President, Global Head - Clinical Development

Ms. Jennifer Fine

Senior Vice President, Global Head - HEOR and RWE

Mr. Kim Kelly

Chief Technical Officer

Dr. Keith Fournier, Ph.D.

Senior Vice President - Global Regulatory Affair

Dr. Maurus de la Rosa, Ph.D.

Senior Vice President - Research

詳細を見る

会社名